Loading clinical trials...
Loading clinical trials...
Phase IIa, Placebo-controlled, Randomized, Double-blind, Crossover Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 (8%) Administered by Nebulization in Subjects With Mild Atopic Asthma.
Conditions
Interventions
S1226(8%)
Placebo
Locations
1
Canada
Respiratory Clinical Trials Centre, University of Calgary
Calgary, Alberta, Canada
Start Date
February 6, 2015
Primary Completion Date
November 25, 2015
Completion Date
November 25, 2015
Last Updated
February 18, 2019
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
SolAeroMed Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions